Origin Speech Therapy Inc.

SAN FRANCISCO, CA · Founded 2024 · CIK 0002098687 · Biotech

Multimodal cancer biology datasets from patient tumor tissue integrating spatial transcriptomics, morphology, proteomics, and ex vivo perturbation data

origin.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.6M
1 Form D · Dec 2025
10 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,634,991
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2257Biomed Protect, LLC—$2.0M
2258EnKay Omics, Inc.——
2259KARAMEDICA, INC.——
2260Origin Speech Therapy Inc.—$2.6M
2261TRAMPOLINE PHARMA, INC.——
2262HEMATHERIX LLC——
2263TACIT THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Gabriel HartDirector · Executive Officer
  • Ni XuDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.